Home Biosimilar Antibodies Others CD markers Alemtuzumab (Anti-CD52)
For research use only. Not for use in humans.

Alemtuzumab (Anti-CD52)

Synonyms: Campath-IH

Alemtuzumab (Anti-CD52) is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD.

Alemtuzumab (Anti-CD52)

Quality Control

Batch: Purity: 99% Protein concentration: 9.336mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Alemtuzumab (Anti-CD52) is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD.

Product Details

CAS No. 216503-57-0
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06358638 RECRUITING Drug: Daratumumab|Drug: Alemtuzumab|Drug: Sirolimus Sickle Cell Disease Children's National Research Institute 2024-04-03 PHASE2
NCT07616154 RECRUITING Drug: Cyclophosphamide 50mg|Drug: Abatacept|Drug: Alemtuzuma Sickle Cell Disease St. Jude Children's Research Hospital 2026-09 PHASE2
NCT03910452 ACTIVE_NOT_RECRUITING Drug: Busulfan|Drug: Alemtuzumab|Drug: Cyclophosphamide|Drug Chronic Granulomatous Disease National Institute of Allergy and Infectious Diseases (NIAID) 2019-10-28 EARLY_PHASE1
NCT02395497 RECRUITING Drug: Tacrolimus Amputation; Wounds and Injuries; Amputation, Traumatic; Urologic Surgical Procedures, Male; Amputation, Traumatic/Surgery; Penis/Transplantation; Penis/Surgery; Penis/Injuries; Congenital Anomaly, Male Genitalia Johns Hopkins University 2014-06 PHASE2; PHASE3
NCT05463133 RECRUITING Drug: Sirolimus|Drug: Cyclophosphamide|Drug: Alemtuzumab|Dru Chronic Granulomatous Disease National Institute of Allergy and Infectious Diseases (NIAID) 2022-07-08 PHASE1; PHASE2
NCT07599176 RECRUITING Drug: Alemtuzumab|Drug: Abatacept Sickle Cell Disease; Beta-thalassemia National Heart, Lung, and Blood Institute (NHLBI) 2026-07-08 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2025-09-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.